
Dr Katja Klein
PhD, MSc, MSc
Expertise
Current positions
Lecturer in Endemic, Enzootic and Emerging Infectious Diseases
Bristol Veterinary School
Contact
Press and media
Many of our academics speak to the media as experts in their field of research. If you are a journalist, please contact the University’s Media and PR Team:
Biography
Dr Klein was appointed Lecturer in Endemic, Enzootic and Emerging Infectious Diseases at the University of Bristol Veterinary School in March 2024. Her research focuses on virology, immunology, and cell biology, with particular interest in viral transmission mechanisms and the development of immune responses to globally important pathogens such as HIV-1, SARS-CoV-2, and influenza A virus (IAV). She first joined the University of Bristol in April 2020 as a Postdoctoral Associate, contributing to research on SARS-CoV-2 entry mechanisms, the development of broad-spectrum antivirals, and host–virus interactions in influenza. Prior to this, Dr Klein held postdoctoral positions at the University of Western Ontario (Canada), Case Western Reserve University (USA), and Imperial College London (UK), where she studied HIV–host interactions and vaccine development.
Projects and supervisions
Research projects
α-DGN, a broad-spectrum inhibitor of enveloped viruses
Principal Investigator
Role
Co-Principal Investigator
Managing organisational unit
Bristol Medical School (THS)Dates
02/12/2024 to 01/12/2025
Publications
Recent publications
23/05/2025Transmitted/founder (T/F) HIV-1 derived from sexual contact exhibits greater transmission fitness in human cervical tissue than T/F HIV-1 from blood-to-blood contact: Unique glycan profiles on T/F envelopes associated with transmission phenotypes
PLOS Pathogens
Effective and targeted latency reversal in CD4+ T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection
Emerging Microbes and Infection
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses
Antiviral Research
Enhanced SARS-CoV-2 entry via UPR-dependent AMPK-related kinase NUAK2
Molecular Cell



